Viitteet

  1. Borriello SP Hammes WP Holzapfel W. Safety of probiotics that contain Lactobacilli or Bifidobacteria. Clin. Infect. Dis. 2003 36: 775-780.
  2. Collins JK, Dunne C, Murphy L, Morrissey D, O’Mahoney L, et al. A randomised controlled trial of a probiotic Lactobacillus strain in healthy adults: assessment of its delivery, transit and influence on microbial flora and enteric immunity. Microbial Ecol. Health Dis. 2002 14:81-89.
  3. Walter J Ecological Role of Lactobacilli in the Gastrointestinal Tract: Implications for Fundamental and Biomedical Research Appl. Environ. Microbiol. 2008, 74(16):4985.
  4. Tannock, G.W. 1999a. ”Probiotics A Critical Review.” Horizon Scientific Press, Norfolk, England.
  5. Ahrne’, S., Nobaek, S., Jeppsson, B., Adlerberth, I., Wold, A.E. and Molin, G. (1998) The normal Lactobacillus flora of healthy human rectal and oral mucosa. J Appl Microbiol 85, 88-94.
  6. Walter J Ecological Role of Lactobacilli in the Gastrointestinal Tract: Implications for Fundamental and Biomedical Research Appl. Environ. Microbiol. 2008, 74(16):4985.
  7. Sanders, M.E. ”The Scientific Basis of Lactobacillus acidophilus Functionally as a Probiotic”. Journal of Dairy Sciences. 2001. Volume 84. Sivut 319–331.
  8. Mitsuoka, T (1992) Intestinal flora and aging. Nutr Rev 50, 438-446.
  9. Ohland et al. Probiotic bacteria and intestinal epithelial barrier function. American Journal of Physiology, GI June 1, 2010 vol. 298. 6.
  10. ibid.
  11. ibid.
  12. ibid.
  13. Borruel N, Carol M, Casellas F et al. Increased mucosal TNF-a production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria. Gut 2002;51:659-64.
  14. Ohland et al. Probiotic bacteria and intestinal epithelial barrier function. American Journal of Physiology, GI June 1, 2010 vol. 298. 6.
  15. Begley M et al Bile Salt Hydrolase Activity in Probiotics. Appl Environ Microbiol. 2006 March; 72(3): 1729-1738.
  16. Hill MJ. Intestinal flora and endogenous vitamin synthesis. European Journal of Cancer Prevention. 1997, 6 Suppl 1:S43-5.
  17. FAO/WHO Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/WHO Expert Consultation 2001.
  18. Huys, G. et al. Accuracy of species identity of commercial bacterial cultures intended for probiotic or nutritional use. Res Microbiol 2006: 157, 803-810.
  19. Richard V, Van der Auwera P Snoeck R, Daneau D, Meunier F Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988;7:783-5.
  20. Spinosa MR, Wallet F Courcol RJ, Oggioni MR. The trouble in tracing opportunistic pathogens: cholangitis due to Bacillus in a French hospital caused by a strain related to an Italian probiotic? Microb Ecol Health Dis 2000;12:99- 101.
  21. Oggioni MR, Pozzi G, Valensin PE, Galieni P Bigazzi C. Recurrent septicemia in an immunocompromised patient due to probiotic strains of Bacillus subtilis. J Clin Microbiol 1998;36:325-6.
  22. Riquelme AJ, Calvo MA, Guzman AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003;36:41-3.
  23. Rautava et al.New therapeutic strategy for combating the increasing burden of allergic disease: Probiotics-A Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J. Allergy Clin. Immunol. 116, 31-37 (2005).
  24. Marteau PR. Probiotics in clinical conditions. Clin Rev Allergy Immunol 2002;22:255-73.
  25. Kleessen et al,. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr. 1997 May;65(5):1397-402.
  26. Boehm et al. Supplementation of a bovine milk formula with an oligosaccharide mixture increases counts of faecal bifidobacteria in preterm infants . Arch Dis Child Fetal Neonatal Ed. 2002 May;86(3):F178-81.
  27. Smith A et al. Effect of a synbiotic on microbial community structure in a continuous culture model of the gastric microbiota in enteral nutrition patients Microbiol Ecol (2012) 80; 135-145.
  28. Rafii et al Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag. 2008;4(6):1343-58.
  29. Jernberg C, Lofmark S, Edlund C, Jansson JK. Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 2010 ;156:3216-23.
  30. Plummer et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004 Mar;7(1):59-62.
  31. Hempel et al. Probiotics for the prevention and treatment of antibiotic- associated diarrhea: a systematic review and meta-analysis. JAMA. 2012 9;307(18):1959-69.
  32. ibid.
  33. Madden et al. Effect of probiotics on preventing disruption of the intestinal microflora following antibiotic therapy: a double-blind, placebo-controlled pilot study. Int Immunopharmacol. 2005;5(6):1091-7.
  34. Plummer et al. Effects of probiotics on the composition of the intestinal microbiota following antibiotic therapy. Int Microbial Agents. 2005;26 (1): 69-74.
  35. Plummer et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol. 2004 Mar;7(1):59-62.
  36. Johnson et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012 Nov;16(11):e786-92.
  37. Anaerobe. 2012 Oct;18(5):489-97.
  38. Bujnakova et al. Inhibitory potential of lactobacilli against Escherichia coli internalization by HT 29 cells. Folia Microbiol (Praha). 2012 Jul;57(4):269-72.
  39. Chen et al. Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells. J Food Sci. 2012 Jan;77(1):M9-14.
  40. Asa Hakansson and Goran Molin. Gut Microbiota and Inflammation. Nutrients. 2011 June; 3(6): 637-682.
  41. Sierra S, Lara-Villoslada F Sempere L, Olivares M, Boza J, Xaus J. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults..Anaerobe. 2010 Jun;16(3):195-200.
  42. Mondel M, et al. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans. Mucosal Immunol. 2009 Mar;2(2):166-72.
  43. Lamprecht M et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double- blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012 Sep 20;9(1):45.
  44. Lamprecht M et al. Probiotic supplementation affects markers of intestinal barrier, oxidation, and inflammation in trained men; a randomized, double- blinded, placebo-controlled trial. J Int Soc Sports Nutr. 2012 Sep 20;9(1):45.
  45. Clavel T & Haller D Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation. Current issues in intestinal microbiology 2007;8(2):25-43.
  46. Sierra et al. Intestinal and immunological effects of daily oral administration of Lactobacillus salivarius CECT5713 to healthy adults. Anaerobe. 2010 Jun;16(3):195-200.
  47. O’Callaghan J Influence of adhesion and bacteriocin production by Lactobacillus salivarius on the intestinal epithelial cell transcriptional response.Appl Environ Microbiol. 2012 Aug;78(15):5196-203.
  48. Sazawal S, Hiremath G, Dhingra U, et al; Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006 Jun;6(6):374-82.
  49. Sudha MR, Maurya AK. Effect of oral supplementation of the probiotic capsule UB-01BV in the treatment of patients with bacterial vaginosis. Benef Microbes. 2012 Jun 1;3(2):151-5.
  50. Ya W, Reifer C, Miller LE. Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol. 2010 Aug;203(2):120.e1-6.
  51. Williams E, Stimpson J, Wang D, Plummer S, Garaiova I, Barker M, Corfe B. Clinical Trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo controlled study. Aliment Pharmacol Ther 2008.
  52. Krznaric Z, Vranesic Bender D, Kunovic A, Kekez D, Stimac D. Gut microbiota and obesity. Dig Dis. 2012;30(2):196-200.
  53. Ilmonen J, Isolauri E, Poussa T, Laitinen K. Impact of dietary counselling and probiotic intervention on maternal anthropometric measurements during and after pregnancy: a randomized placebo-controlled trial. Clin Nutr. 2011 Apr;30(2):156-64.
  54. Wang S, Zhang J, Wang M, Du G, Chen J. Removal of microcystin-LR by lactic acid bacteria. Wei Sheng Wu Xue Bao. 2010;50(6):729-35.
  55. Kumar M et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res. 2012;2012:902917.
  56. Begley M, Hill C, Gahan CGM. Bile salt hydrolase activity in probiotics. Appl environ Microbiol 2006, 72;1729-1738.
  57. Bjorksten et al. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy. 1999 Mar;29(3):342-6.
  58. Allen SJ et al Probiotics and atopic eczema: a double-blind randomised controlled trial. Arch Dis Child 2012;97:Suppl 1 A2.
  59. Pelucchi C,Chatenoud L, Turati F Galeone C, Moja L, Bach J, La Vecchia C.a,b. Probiotics Supplementation During Pregnancy or Infancy for the Prevention of Atopic Dermatitis A Meta-analysis Epidemiology 2012;23: 402-414.
  60. Mathenthiralingham et al. Use of colony-based bacterial strain typing for tracking the fate of Lactobacillus strains during human consumption. BMC microbiology 2009; 9; 251.